Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ELOC

Gene summary for ELOC

Gene summary.

Gene information	Species	Human
	Gene symbol	ELOC
	Gene ID	6921
	Gene name	elongin C
	Gene Alias	SIII
	Cytomap	8q21.11
	Gene Type	protein-coding
	GO ID	GO:0006139
	UniProtAcc	A0A024R7Y5

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
6921	ELOC	GSM4909281	Human	Breast	IDC	2.00e-28	6.61e-01	0.21
6921	ELOC	GSM4909282	Human	Breast	IDC	2.55e-25	7.15e-01	-0.0288
6921	ELOC	GSM4909285	Human	Breast	IDC	2.69e-16	4.66e-01	0.21
6921	ELOC	GSM4909286	Human	Breast	IDC	4.10e-23	3.31e-01	0.1081
6921	ELOC	GSM4909289	Human	Breast	IDC	1.95e-03	5.05e-01	0.1064
6921	ELOC	GSM4909290	Human	Breast	IDC	1.39e-07	3.70e-01	0.2096
6921	ELOC	GSM4909291	Human	Breast	IDC	5.34e-46	1.03e+00	0.1753
6921	ELOC	GSM4909293	Human	Breast	IDC	8.82e-08	1.36e-01	0.1581
6921	ELOC	GSM4909295	Human	Breast	IDC	1.60e-05	4.41e-01	0.0898
6921	ELOC	GSM4909296	Human	Breast	IDC	8.58e-07	3.53e-01	0.1524
6921	ELOC	GSM4909297	Human	Breast	IDC	1.62e-05	2.16e-01	0.1517
6921	ELOC	GSM4909298	Human	Breast	IDC	3.25e-08	1.85e-01	0.1551
6921	ELOC	GSM4909301	Human	Breast	IDC	1.68e-02	3.40e-01	0.1577
6921	ELOC	GSM4909304	Human	Breast	IDC	2.69e-06	2.86e-01	0.1636
6921	ELOC	GSM4909305	Human	Breast	IDC	1.15e-09	4.17e-01	0.0436
6921	ELOC	GSM4909306	Human	Breast	IDC	1.38e-26	7.01e-01	0.1564
6921	ELOC	GSM4909307	Human	Breast	IDC	7.59e-09	4.28e-01	0.1569
6921	ELOC	GSM4909308	Human	Breast	IDC	4.45e-15	4.06e-01	0.158
6921	ELOC	GSM4909309	Human	Breast	IDC	1.77e-03	3.23e-01	0.0483
6921	ELOC	GSM4909311	Human	Breast	IDC	7.21e-19	2.08e-01	0.1534

Page: 1 2 3 4 5 6 7 8 9

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

Count

Page: 1

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0521110	Prostate	BPH	Renal cell carcinoma	26/1718	69/8465	6.25e-04	3.08e-03	1.90e-03	26
hsa0517020	Prostate	BPH	Human immunodeficiency virus 1 infection	60/1718	212/8465	2.96e-03	1.12e-02	6.92e-03	60
hsa0412019	Prostate	BPH	Ubiquitin mediated proteolysis	61/1718	142/8465	5.50e-10	9.07e-09	5.61e-09	61
hsa04066111	Prostate	BPH	HIF-1 signaling pathway	40/1718	109/8465	4.97e-05	3.35e-04	2.07e-04	40
hsa0521115	Prostate	BPH	Renal cell carcinoma	26/1718	69/8465	6.25e-04	3.08e-03	1.90e-03	26
hsa05170110	Prostate	BPH	Human immunodeficiency virus 1 infection	60/1718	212/8465	2.96e-03	1.12e-02	6.92e-03	60
hsa0412024	Prostate	Tumor	Ubiquitin mediated proteolysis	61/1791	142/8465	3.08e-09	5.09e-08	3.16e-08	61
hsa0406626	Prostate	Tumor	HIF-1 signaling pathway	41/1791	109/8465	5.67e-05	4.27e-04	2.65e-04	41
hsa0521124	Prostate	Tumor	Renal cell carcinoma	26/1791	69/8465	1.20e-03	5.23e-03	3.25e-03	26
hsa0517026	Prostate	Tumor	Human immunodeficiency virus 1 infection	62/1791	212/8465	3.05e-03	1.12e-02	6.94e-03	62
hsa0412034	Prostate	Tumor	Ubiquitin mediated proteolysis	61/1791	142/8465	3.08e-09	5.09e-08	3.16e-08	61
hsa0406635	Prostate	Tumor	HIF-1 signaling pathway	41/1791	109/8465	5.67e-05	4.27e-04	2.65e-04	41
hsa0521134	Prostate	Tumor	Renal cell carcinoma	26/1791	69/8465	1.20e-03	5.23e-03	3.25e-03	26
hsa0517036	Prostate	Tumor	Human immunodeficiency virus 1 infection	62/1791	212/8465	3.05e-03	1.12e-02	6.94e-03	62
hsa0406610	Stomach	GC	HIF-1 signaling pathway	20/708	109/8465	6.21e-04	5.23e-03	3.68e-03	20
hsa051708	Stomach	GC	Human immunodeficiency virus 1 infection	30/708	212/8465	2.91e-03	1.76e-02	1.24e-02	30
hsa0406611	Stomach	GC	HIF-1 signaling pathway	20/708	109/8465	6.21e-04	5.23e-03	3.68e-03	20
hsa0517011	Stomach	GC	Human immunodeficiency virus 1 infection	30/708	212/8465	2.91e-03	1.76e-02	1.24e-02	30
hsa0517021	Stomach	CAG with IM	Human immunodeficiency virus 1 infection	29/640	212/8465	1.26e-03	8.93e-03	6.27e-03	29
hsa0406621	Stomach	CAG with IM	HIF-1 signaling pathway	18/640	109/8465	1.26e-03	8.93e-03	6.27e-03	18

Page: 1 2 3 4 5

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ELOC

SNV

Missense_Mutation

c.200N>T

p.Ser67Leu

p.S67L

Q15369

protein_coding

deleterious(0.01)

benign(0.061)

TCGA-AR-A256-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

ELOC

SNV

Missense_Mutation

c.122N>T

p.Thr41Met

p.T41M

Q15369

protein_coding

tolerated(0.05)

possibly_damaging(0.604)

TCGA-AD-5900-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

ELOC

insertion

In_Frame_Ins

novel

c.192_193insTTCAACTGC

p.Glu64_Ile65insPheAsnCys

p.E64_I65insFNC

Q15369

protein_coding

TCGA-F4-6703-01

Colorectum

colon adenocarcinoma

Male

<65

I/II

Unknown

ELOC

SNV

Missense_Mutation

novel

c.212C>T

p.Ser71Leu

p.S71L

Q15369

protein_coding

tolerated(0.25)

benign(0.003)

TCGA-A5-A2K5-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

ELOC

SNV

Missense_Mutation

novel

c.158N>A

p.Ala53Asp

p.A53D

Q15369

protein_coding

deleterious(0.02)

benign(0.367)

TCGA-AJ-A3EK-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Chemotherapy

carboplatin

ELOC

SNV

Missense_Mutation

c.256A>G

p.Ser86Gly

p.S86G

Q15369

protein_coding

deleterious(0.01)

benign(0.284)

TCGA-AP-A05N-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

ELOC

SNV

Missense_Mutation

c.122N>T

p.Thr41Met

p.T41M

Q15369

protein_coding

tolerated(0.05)

possibly_damaging(0.604)

TCGA-B5-A11E-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

ELOC

SNV

Missense_Mutation

novel

c.272N>A

p.Pro91His

p.P91H

Q15369

protein_coding

deleterious(0)

possibly_damaging(0.481)

TCGA-B5-A1MX-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Hormone Therapy

megace

ELOC

SNV

Missense_Mutation

rs762993549

c.233N>T

p.Thr78Met

p.T78M

Q15369

protein_coding

tolerated(0.18)

benign(0.067)

TCGA-EO-A22R-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

ELOC

SNV

Missense_Mutation

novel

c.158C>T

p.Ala53Val

p.A53V

Q15369

protein_coding

tolerated(0.08)

benign(0.056)

TCGA-EO-A22U-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

Page: 1 2

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1